Eric Yang, MD
(he/him)
Languages
Education
Fellowship
Internship
Degrees
Residencies
Board Certifications
Contact Information
Scientific Interests
As the Director and Founder of the UCLA Cardio-Oncology Program, Dr. Yang's clinical and research interests have been focused on the elucidation of the mechanistic overlap between cardiovascular disease and cardiotoxicity induced by both historical and more modern novel cancer treatments. He currently balance an active clinical practice in providing timely care, cardiovascular risk stratification, and cardiotoxicity diagnosis/treatment of the cancer population of UCLA Health, and also conduct clinical research in 1) defining clinical characteristics of patients who develop cardiotoxicity in all cancer disease statements and/or treatments, and 2) formulate cardioprotective strategies in detecting, and attenuating subclinical cardiotoxicity.
Highlighted Publications
Vascular Toxicities of Cancer Therapies: The Old and The New—An Evolving Avenue. Joerg Herrmann, Eric H Yang, Cezar Iliescu, Cindy Grines, Mehmet Cilingiroglu, Kostantinos Charitakis, Abdul Hakeem, Konstantinos Toutouzas, Massoud A Lessar, Konstantinos Marmagkiolis. Circulation. 133(13):1272-89.doi:10.1161/CIRCULATIONAHA.115.018347. 2016.
Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry. David M Tehrani, Xiaoyan Wang, Asim M Rafique, Salim S Hayek, Joerg Herrmann, Tomas G Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V Parikh, Eric H Yang. Cardio-Oncology 2021;7, 28.
Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Ohad Oren, Eric H Yang, Julian R Molina, Kent R Bailey, Roger S Blumenthal, Stephen L Kopecky. Am J Card 2020 pii: S0002-9149(20)30186-7. doi: 10.1016/j.amjcard.2020.02.016.
Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis. Lily Zhang, Magid Awadalla, Syed S Mahmood...Eric H Yang, et al. Eur Heart J 2020; pii: ehaa051. doi: 10.1093/eurheartj/ehaa051.
Cardiotoxicities of Novel Cancer Immunotherapies. Ashley F Stein-Merlob, Michael V Rothberg, Antoni Ribas, Eric H Yang. Heart. 2021 Mar 15:heartjnl-2020-318083. doi: 10.1136/heartjnl-2020-318083.
